13 Results for "

PAS-B domain

" in MedChemExpress (MCE) Product Catalog:
Products (13)

13 Results for "PAS-B domain" in MCE Product Catalog:

11
11 Cited Publications
Art. -Nr.: HY-108697
CAS. Nr.: 1672662-14-4
Reinheit:  99.90%
Forschungsgebiete:  

Cancer

PT2399 is a potent and selective HIF-2α antagonist, which directly binds to HIF-2α PAS B domain with an IC50 of 6 nM. PT2399 displays potent antitumor activity in vivo .
loading...
    loading...
Art. -Nr.: HY-19621
CAS. Nr.: 62054-67-5
Forschungsgebiete:  

Cancer

THS-044 is a modulator of the formation of the HIF2α/ARNT heterodimer. THS-044 binding stabilizes the HIF2α PAS-B folded state (KD = 2 μM), for regulating HIF2 activity in endogenous and pathological settings, and does not bind to HIF1α or ARNT PAS-B. THS-044 can be used for the study of diseases related to hypoxia .
loading...
    loading...
Art. -Nr.: HY-120087
CAS. Nr.: 175205-09-1
Reinheit:  99.92%
Forschungsgebiete:  

Cancer

KG-548 is an ARNT/TACC3 disruptor and a HIF-1α inhibitor. KG-548 directly interferes with ARNT/TACC3 complex formation by competing with TACC3 for binding to the ARNT PAS-B domain. ARNT is the aryl hydrocarbon receptor nuclear translocator, also known as HIF-β .
loading...
    loading...
Art. -Nr.: HY-111547
CAS. Nr.: 874590-32-6
Reinheit:  99.51%
Forschungsgebiete:  

Cancer

M1001 is a weak hypoxia-inducible factor-2α (HIF-2α) agonist. M1001 can bind to the HIF-2α PAS-B domain, with a Kd of 667 nM. M1001 can be used in chronic kidney disease research .
loading...
    loading...
Art. -Nr.: HY-P10221A
Forschungsgebiete:  

Cancer

Cyclo(CKLIIF) TFA is an inhibitor of HIF-1α and HIF-2α. The KD values of Cyclo(CKLIIF) TFA for the PAS-B domains of HIF1-α and HIF2-α are 2.6 μM and 2.2 μM, respectively. Cyclo(CKLIIF) TFA disrupts the protein-protein interaction between HIF-1α and HIF-1β. Cyclo(CKLIIF) TFA can be used in cancer research .
loading...
    loading...
Art. -Nr.: HY-P10426
CAS. Nr.: 1446322-73-1
Forschungsgebiete:  

Cancer

cyclo(CLLFVY) is an inhibitor for hypoxia inducible factor-1 (HIF-1), with IC50 of 19 μM (in U2OS) and 16 μM (in MCF-7). cyclo(CLLFVY) binds to the PAS-B domain of HIF-1α, inhibits HIF-1 dimerization and transcriptional activity. cyclo(CLLFVY) downregulates the expression of hypoxia response genes, such as VEGF and CAIX, exhibits antitumor against the HIF-1 associated cancers .
loading...
    loading...
Art. -Nr.: HY-P10222
Forschungsgebiete:  

Cancer

Cyclo CRLLIF is a dual inhibitor for hypoxia inducible factor (HIF) 1 and 2, which disrupts the interaction of both HIF1-α and HIF2-α with HIF1-β, with affinity for HIF1-α and HIF2-α PAS-B domains KD of 14.5 and 10.2 μM, respectively .
loading...
    loading...
Art. -Nr.: HY-W012248
CAS. Nr.: 349-58-6
Target:  

FGFR

Forschungsgebiete:  

Cancer

KG-655 is a ligand that specifically binds to the ARNT PAS-B domain. KG-655 binds to the internal cavity of ARNT PAS-B to restrict its variable folded conformation, disrupts the interaction between ARNT PAS-B and the transcriptional coactivator TACC3, and promotes the homodimerization of ARNT PAS-B. KG-655 is widely applicable to cancer-related research .
loading...
    loading...
Art. -Nr.: HY-P10223
Forschungsgebiete:  

Cancer

Cyclo CRVIIF is a dual inhibitor for hypoxia inducible factor (HIF) 1 and 2, which disrupts the interaction of both HIF1-α and HIF2-α with HIF1-β, with affinity for HIF1-α and HIF2-α PAS-B domains KD of 65 and 123 μM, respectively .
loading...
    loading...
Art. -Nr.: HY-W470101
CAS. Nr.: 861212-49-9
Forschungsgebiete:  

Cancer

HIF-2α-IN-17 is a selective hypoxia-inducible factor 2α (HIF2α) inhibitor that binds to the PAS-B domain of HIF2α. HIF-2α-IN-17 disrupts the interaction between HIF2α and the molecular chaperone Hsp70, leading to proteasomal degradation of HIF2α. HIF-2α-IN-17 exhibits antitumor activity and induces apoptosis in cancer cells. HIF-2α-IN-17 is applicable for research on cancers such as clear cell renal cell carcinoma .
loading...
    loading...
Art. -Nr.: HY-183583
CAS. Nr.: 2709068-47-1
Forschungsgebiete:  

Cancer

HIF-2α-IN-18 is a selective HIF-2α inhibitor with a human IC50 of 8.1 nM. HIF-2α-IN-18 binds to the HIF-2α PAS-B domain, induces conformational perturbations at the HIF-2α/ARNT dimerization interface, destabilizes the HIF-2α/ARNT heterodimer, and blocks HIF-2α-mediated transcriptional activity. HIF-2α-IN-18 inhibits hypoxia-induced expression of HIF-2α target genes EPO and SERPINE1, without inhibiting HIF-1α target genes PGK1 and PDK1. HIF-2α-IN-18 can be used for the research of clear cell renal cell carcinoma, hepatocellular carcinoma[1].
loading...
    loading...
Art. -Nr.: HY-108697R
CAS. Nr.: 1672662-14-4
Forschungsgebiete:  

Cancer

PT2399 (Standard) is the analytical standard of PT2399 (HY-108697). This product is intended for research and analytical applications. PT2399 is a potent and selective HIF-2α antagonist, which directly binds to HIF-2α PAS B domain with an IC50 of 6 nM. PT2399 displays potent antitumor activity in vivo .
loading...
    loading...
Art. -Nr.: HY-181270
CAS. Nr.: 301335-35-3
Forschungsgebiete:  

Cancer

RH01504 is a HIF2α inhibitor with a Kd value of 5.42 nM against human HIF2α. RH01504 inhibits the growth of renal cancer cells. RH01504 can be used in research related to renal cell carcinoma .
loading...
    loading...
  • 1